br Bartlett FR Colgan RM Carr
20. Bartlett FR, Colgan RM, Carr K, et al. The UK HeartSpare Study: randomised evaluation of voluntary deep-inspiratory breath-hold in women undergoing breast radiotherapy. Radiother Oncol. 2013;108: 242-247.
21. Schultz-Hector S, Trott KR. Radiation-induced cardiovascular dis-eases: Is the epidemiologic evidence compatible with the radiobio-logic data? Int J Radiat Oncol Biol Phys. 2007;67:10-18.
24. Van Den Bongaard VAB, Ta BD, van der Schaaf A, et al. Valida-tion and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures. J Clin Oncol. 2017;35:1171-1178.
25. van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2015;34:235-243.
26. Carroll RJ, Ruppert D, Stefanski LA, Crainiceanu CM. Measure-ment error in nonlinear models: A modern perspective. 2nd ed.
London, United Kingdom: Chapman & Hall/CRC Monographs on Statistics & Applied Probability; 2006.
27. Nilsson G, Nystrom PW, Isacsson U, et al. Radiation dose distri-bution in coronary MDMB-CHMICA M 2 in breast cancer radiotherapy. Acta Oncol. 2016;55:959-963.
28. Krueger EA, Schipper MJ, Koelling T, Marsh RB, Butler JB, Pierce LJ. Cardiac chamber and coronary artery doses associated with postmastectomy radiotherapy techniques to the chest wall and regional nodes. Int J Radiat Oncol Biol Phys. 2004;60:1195-1203.
29. Moignier A, Broggio D, Derreumaux S, et al. Dependence of cor-onary 3-dimensional dose maps on coronary topologies and beam set in breast radiation therapy: A study based on CT angiographies. Int J Radiat Oncol Biol Phys. 2014;89:182-190.
30. Feng M, Moran JM, Koelling T, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10-18.
31. Wang L, Ding GX. The accuracy of the out-of-field dose calcula-tions using a model based algorithm in a commercial treatment planning system. Phys Med Biol. 2014;59:N113.
32. Hector C, Webb S, Evans PM. A simulation of the effects of set-up error and changes in breast volume on conventional and intensity-modulated treatments in breast radiotherapy. Phys Med Biol. 2001; 46:1451.
33. Topolnjak R, Borst GR, Nijkamp J, Sonke JJ. Image-guided radiotherapy for left-sided breast cancer patients: Geometrical un-certainty of the heart. Int J Radiat Oncol Biol Phys. 2012;82:e647-e655.
34. El-Sherif O, Yu E, Xhaferllari I, Gaede S. Assessment of intra-fraction breathing motion on left anterior descending artery dose during left-sided breast radiation therapy. Int J Radiat Oncol Biol Phys. 2016;95:1075-1082.
35. Jagsi R, Moran JM, Kessler ML, Marsh RB, Balter JM, Pierce LJ. Respiratory motion of the heart and positional reproducibility under active breathing control. Int J Radiat Oncol Biol Phys. 2007;68: 253-258.
Contents lists available at ScienceDirect
International Journal of Cardiology
Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
Matthias Totzeck a, Martin Schuler b,e, Martin Stuschke c,e, Gerd Heusch d, Tienush Rassaf a,
a Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany
b Department of Medical Oncology, West German Cancer Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany
c Department of Radiation Oncology, West German Cancer Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany
d Institute for Pathophysiology, West German Heart and Vascular Center, Medical Faculty, University Hospital Essen, Hufelandstr. 55, 45147 Essen, Germany
e German Cancer Consortium (DKTK), Partner site University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
Current therapy of advanced cancers is based on several modalities including radiotherapy, cytotoxic chemother-apy, molecularly targeted inhibitors and antibodies targeting immune checkpoints. All of those these modalities can negatively impact the cardiovascular system, and there is considerable experience in relation to radiotherapy and chemotherapy. In contrast, the knowledge base on cardiovascular toxicities of novel agents targeting signal transduction pathways and immune regulation is quite limited. In particular, potential late effects are of concern as cardiovascular pathology can negatively impact quality of life and prognosis in cancer survivors, particularly when additional cardiovascular risk factors are present. Treatment-associated adverse events include hyperten-sion, venous thromboembolism, coronary artery disease, valvular heart disease, heart failure and arrhythmias. Early diagnosis of subclinical cardiotoxic effects of cancer therapies remains challenging. Integrated care, as pro-vided by multidisciplinary cardio-oncology teams is the best option for prevention, diagnosis and treatment of cardiovascular diseases associated with cancer therapy. This review considers the cardiotoxic effects of specific cancer therapies and discusses novel diagnostic and therapeutic approaches as a reference for optimizing the care of cancer patients receiving novel cancer therapies.